Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

A new study headed by teams at the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), and Open Targets has indicated how mutations that cause cancer drug resistance fall ...

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from ...

Brain cancers are notoriously difficult to treat, with surgery and radiation continuing to be the main options for these malignancies. A rare and aggressive type of brain tumor driven by a particular ...

The pharmaceutical industry says a popular class of targeted cancer therapies could one day replace chemotherapy and its potential for harsh side effects. There is still more work to be done to refine ...

The October 2024 approval of inavolisib for advanced breast cancer spotlighted a growing problem in breast oncology: Managing the hyperglycemia caused by phosphoinositide 3-kinase (PI3K)/Akt pathway ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer. Wednesday, Chinese ...